The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung ...

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...

Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the "go ahead" from European ...

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous ...

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

CHONGQING, CHINA - JULY 27: In this photo illustration, a person holds a smartphone displaying the logo of Merck & Co., Inc. (NYSE: MRK), a leading American multinational pharmaceutical company, with ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...